Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects.
Purpose. We evaluated potential drug-drug interactions between cilostazol and simvastatin, both CYP3A substrates, in healthy subjects. Methods. An open-label, two-period, fixed-sequence clinical study was conducted. Seventeen subjects were given a single oral dose of simvastatin 40 mg on day 1 and m...
| Publicado en: | BioMed Research International pp. 1 - 7 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
1/9/2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=134045239&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 134045239 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 1/9/2019 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 134045239 134045239 134045239 10.1155/2019/1365180 134045239 ppf: 1 ppct: 6 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects. aug: au: Kim, Jung-Ryul Jung, Jin Ah Kim, Seokuee Huh, Wooseong Ghim, Jong-Lyul Shin, Jae-Gook Ko, Jae-Wook affil: Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, Seoul, Republic of Korea sug: subj: Cilostazol Pharmacodynamics Simvastatin Pharmacokinetics Drug Interactions Cytochrome P-450 Enzyme System Drug Effects Cytochrome P-450 Enzyme System Metabolism Human Clinical Trials Simvastatin Blood Chromatography, Liquid Mass Spectrometry Descriptive Statistics Confidence Intervals Cholesterol Blood Triglycerides Blood ab: Purpose. We evaluated potential drug-drug interactions between cilostazol and simvastatin, both CYP3A substrates, in healthy subjects. Methods. An open-label, two-period, fixed-sequence clinical study was conducted. Seventeen subjects were given a single oral dose of simvastatin 40 mg on day 1 and multiple oral doses of cilostazol 100 mg twice daily on days 2 to 5 followed by a single dose of cilostazol and simvastatin on day 6. Plasma concentrations of simvastatin and its active metabolite, simvastatin acid, were measured using liquid chromatography-tandem mass spectrometry for pharmacokinetic assessment. Moreover, serum lipid profiles under fasting conditions were determined. Results. The geometric mean ratios of the area under the plasma concentration-time curve from time zero to time infinity of simvastatin combined with cilostazol to that of simvastatin alone were 1.64 (90% CI, 1.38-1.95) for simvastatin and 1.31 (1.04-1.66) for simvastatin acid. In addition, coadministration with cilostazol significantly increased the maximum concentration of simvastatin and simvastatin acid, up to 1.8-fold and 1.6-fold, respectively. However, the effects of a single dose of simvastatin on serum lipid profiles were not affected notably when simvastatin was coadministered with cilostazol. Conclusions. Multiple doses of cilostazol increased the systemic exposure of simvastatin and simvastatin acid following a single dose of simvastatin. pubtype: Academic Journal doctype: clinical trial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|